GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » icad Inc (NAS:ICAD) » Definitions » Cash per Share

icad (ICAD) Cash per Share : $0.82 (As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is icad Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). icad's Cash per Share for the quarter that ended in Dec. 2023 was $0.82.

icad Cash per Share Historical Data

The historical data trend for icad's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

icad Cash per Share Chart

icad Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.79 1.16 1.36 0.84 0.82

icad Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.78 0.75 0.73 0.82

icad Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

icad's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=21.67/26.35
=0.82

icad's Cash per Share for the quarter that ended in Dec. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=21.67/26.35
=0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

icad  (NAS:ICAD) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

icad Cash per Share Related Terms

Thank you for viewing the detailed overview of icad's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

icad (ICAD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » icad Inc (NAS:ICAD) » Definitions » Cash per Share
Comparable Companies
LFWD RPID LNSR CUTR CODX ECOR CTSO LUCD IINN MDAI ABT SYK BSX MDT XTER:SHL EW SZSE:300760 DXCM ZBH ALGN
Traded in Other Exchanges
N/A
Address
98 Spit Brook Road, Suite 100, Nashua, NH, USA, 03062
Website
https://www.icadmed.com
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company reports in two segments: Detection and Therapy. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.
Executives
Eric Lonnqvist officer: See Remarks 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 02062
Daniel Joseph Shea officer: See Remarks 2 MINUTEMAN ROAD, MEDFIELD MA 02052
Jonathan Go officer: Sr. VP of R&D C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Stephen P Sarno officer: See Remarks C/O SAPIENT CORPORATION, 25 FIRST STREET, CAMBRIDGE MA 02141
Andy Sassine director 82 DEVONSHIRE STREET, BOSTON MA 02109
Dana R Brown director 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Timothy Norris Irish director 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Nathaniel Dalton director C/O AFFILIATED MANAGERS GROUP INC, 777 S. FLAGLER DR., SUITE 1201 E. TOWER, WEST PALM BEACH FL 33401
Susan Alyson Wood director 845 MORENO AVENUE, PALO ALTO CA 94303
Michael S Klein director C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
Charles Ross Carter officer: See Remarks C/O GI DYNAMICS, INC., 745 ATLANTIC AVENUE, BOSTON MA 02111
Stacey M Stevens officer: Executive VP of Marketing C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
R. Scott Areglado officer: Interim Chief FinancialOfficer 98 SPIT BROOK ROAD, SUITE 100, C/O ICAD, INC., NASHUA NH 03062
Rakesh Patel director 15400 NATIONAL AVENUE, LOS GATOS CA 95032
Dr Lawrence Howard director C/O PRESSTEK INC, 2 GREENWICH OFFICE PARK, GREENWICH CT 06831